免疫抑制剂治疗过程中HBV再激活人群危险因素分析

摘要/Abstract

摘要： 目的探讨免疫抑制剂或化疗药物治疗后HBsAg阳性或抗-HBc阳性人群发生HBV再激活(hepatitis B virus reactivation,HBVr)的危险因素。方法回顾性分析2010年1月至2017年1月上海市长海医院HBsAg阳性或HBsAg阴性而抗-HBc阳性238例患者的临床资料,接受免疫抑制剂治疗后,根据随访结果分为发生HBVr组与未发生HBVr组,分析HBVr发生的危险因素。结果 238例患者中,发生HBVr的患者为33例(13.87%)。logistic回归模型提示:有无抗病毒治疗(OR=0.022,95%CI:0.001～0.34),HBV DNA基线水平(OR=15.352,95%CI:3.809～86.160),化疗方案(OR=0.361,95%CI:0.068～1.929),为发生HBVr的独立危险因素。根据变量筛选的结果,建立了预判HBVr风险的回归方程:-4.78×抗病毒干预(有=1,无=0)+2.731×HBV DNA(≥104=1,＜104=0)+3.272×化疗方案(A=3,B=2,C=1)+3.355,以及相应的评分系统。结论 HBVr的发生与有无抗病毒治疗、HBV DNA基线水平以及化疗方案的选择等因素有关,建立模型有助于对HBVr进行预测。

关键词: 乙肝再激活, 免疫抑制, 预测, 危险因素

Abstract: Objective To investigate the risk factors of hepatitis B virus reactivation (HBVr) in HBsAg positive or anti-HBc positive chronic hepatitis B (CHB) patients after treated with immunosuppressants or chemotherapy drugs.Methods HBsAg positive CHB patients and HBsAg negative but anti-HBc positive CHB patients who received immunosuppressive therapy were retrospectively analyzed, the number of the patients was 238. According to the follow-up results, they were divided into HBVr group and non-HBVr group.The risk factors of HBVr were analyzed.Results The average age of 238 patients was 49 ± 14 years old, including 134 males (36.3%) and 33 HBVr patients (13.87%). Logistic regression model showed that there were significant differences between the two groups in whether received antiviral therapy (OR=0.022,95%Cl: 0.001～0.34), (P<0.001), baseline level of HBV DNA (OR=15.352,95%Cl:3.809～86.160), (P<0.001) and chemotherapy regimen (OR=0.361,95%Cl:0.068～1.929), (P=0.023), which were independent risk factors of HBVr. According to the results of variable screening, the regression equation for predicting the risk of HBVr was established as follows: -4.78×antiviral intervention (yes=1, no=0)+2.731×HBV DNA (≥104=1, <104=0)+3.272×chemotherapy regimen (A=3, B=2, C=1)+3.355, and the corresponding scoring system was also established.Conclusion HBVr is related to whether patients received antiviral therapy, the baseline level of HBV DNA and the choice of chemotherapy regimen. The new model will be helpful in predicting the risk of HBVr.

Key words: Hepatitis B virus reactivation, Immunosuppression, Prognosis, Risk factors

范文瀚, 梁雪松, 陈怡, 廖威, 李成忠. 免疫抑制剂治疗过程中HBV再激活人群危险因素分析[J]. 肝脏, 2021, 26(8): 843-846.

FAN Wen-han, LIANG Xue-song, CHEN Yi, LIAO Wei, LI Cheng-zhong. Analysis of risk factors of hepatitis B virus reactivation during immunosuppressive therapy——A new model establishment[J]. Chinese Hepatolgy, 2021, 26(8): 843-846.

参考文献

[1] Shouval D,Shibolet O.Immunosuppression and HBV reactivation. Semin Liver Dis,2013,33:167-177.
[2] Ozoya OO,Sokol L,Dalia S.Hepatitis B reactivation with novel agents in nonHodgkin’s lymphoma and prevention strategies.J Clin Transl Hepatol,2016,4:143-150.
[3] Perrillo RP,Gish R,Falck-Ytter YT,et al.American Gastroenterological Association Institute Technical Review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.Gastroenterology,2015,148:221-244.e3.
[4] Tavakolpour S,Alavian SM,Sali S.Hepatitis B reactivation during immunosuppressive therapy or cancer chemotherapy,management,and prevention: a comprehensive reviewscreened. Hepat Mon,2016,16:e35810.
[5] Bessone F,Dirchwolf M.Management of hepatitis B reactivation in immunosuppressed patients:an update on current recommendations.World J Hepatol,2016,8:385-394.
[6] Tsutsumi Y,Yamamoto Y,Ito S,et al.Hepatitis B virus reactivation with a rituximabcontaining regimen.World J Hepatol,2015,7:2344-2351.
[7] Mozessohn L, Chan KK, Feld JJ,et al.Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis. J Viral Hepat,2015,22:842-849.
[8] Kusumoto S,Tanaka Y,Suzuki R,et al. Monitoring of hepatitis B virus (HBV) DNA and risk of HBV reactivation in B-cell lymphoma: a prospective observational study,Clin Infect Dis, 2015,61:719-729.
[9] 中华医学会感染病学分会,中华医学会肝病学分会,慢性乙型肝炎防治指南(2019版),中华肝脏病杂志,2019,27:938-961.
[10] Seto WK,Chan TS,Hwang YY,et al.Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximabcontaining chemotherapy for lymphoma: a prospective study.J Clin Oncol,2014,32:3736-3743.
[11] Vitolo U,Trneny M,Belada D,et al.Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol,2017,35:3529-3537.
[12] Marcus R,Davies A,Ando K,et al.Obinutuzumab for the first-line treatment of follicular lymphoma.N Engl J Med,2017,377:1331-1344.
[13] Castelli R,Ferraris L,Pantaleo G,et al.High rate of hepatitis B viral breakthrough in elderly non-Hodgkin lymphomas patients treated with Rituximab based chemotherapy. Dig Liver Dis,2016,48:1394-1397.
[14] Grossi G,Vigano M,Facchetti F,et al.Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogenic hematopoietic stem cell transplantation for hematological malignancies: two case reports. Haematologica,2017,102:e423-e426.
[15] Kim SJ,Hsu C,Song Y-Q,et al.Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group. Eur J Cancer,2013,49:3486-3496.
[16] Huang H,Li X,Zhu J,et al.Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy:a randomized clinical trial,JAMA, 2014,312:2521-2530.
[17] Dominguez N,Manzano ML,Muñoz R,et al.Late reactivation of occult hepatitis B virus infection in a patient with chronic lymphocytic leukemia after rituximab and flfludarabine-based regimen.Leuk Lymphoma,2015,56:1160-1163.
[18] Nakaya A,Fujita S,Satake A,et al.Delayed HBV reactivation in rituximab-containing chemotherapy: how long should we continue anti-virus prophylaxis or monitoring HBV DNA? Leuk Res,2016,50:46-49.
[19 Paul S,Dickstein A,Saxena A,et al.Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy:a meta-analysis.Hepatology,2017,66:379-388.
[20] Sampedro B,Hernandez-Lopez C,Ferrandiz JR,et al.Computerized physician order entrybased system to prevent HBV reactivation in patients treated with biologic agents: the PRESCRIB project.Hepatology,2014,60: 106-113.
[21] Notsumata K,Kumai T,Ueda T,et al.Automated risk management of HBV reactivation by encoding patients’ medical records. Kanzo,2014,55:91-99.